You are here: Industry Insights > migraine drug

News List

Amgen’s New Products Deliver Double-Digit Growth While Facing Down Pricing Pressure for New Migraine Drug biospace
April 26, 2018
In its first-quarter earnings report, Thousand Oaks, California-based Amgen cited total revenue for the quarter of $5.6 billion, up 2 percent compared to the first quarter of 2017.
Amgen's Migraine Drug Heads Toward Possible May Approval biospace
April 19, 2018
Amgen announced final data from its Phase IIIb LIBERTY clinical trial of Aimovig (erenumab), with positive results likely to lead to a blockbuster drug for migraine sufferers.
Amgen Jumps as Migraine Drug Wows in Late-Stage Study biospace
January 24, 2018
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
Novartis files migraine drug with EMA pharmaphorum
June 22, 2017
Novartis has filed its migraine drug erenumab with the EMA, putting it in pole position among a group of pharma companies racing to develop a new class of drugs to treat the debilitating condition.

Previous page 1 2 Next page